1Sandrine T,Yohann W,Steeve KT,et al.The molecular triad OPG/RANK/RANKL:involvement in the orchestration of pathophysiological bone remodeling.Cytokine Growth Factor Rev,2004,15:457-475.
2Suda T,Takahashi N,Udagawa N,et al.Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.Endocine Rew,1999,20:345-357.
3Min H,Morony MH,Sarosi I,et al.Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis.J Exp Med,2000,192:463-474.
4Simonet WS,Lacey DL,Dunstan CR,et al.Osteoprotegerin:a novel secreted protein involved in the regulation of bone density.Cell,1997,89:309-319.
5Kim HH,Lee DE,Shin JN,et al.Receptor activator of NF-kappaB recruits multiple TRAF family adaptors and activates c-Jun N-terminal kinase.FEBS Lett,1999,443:297-302.
6Fata JE,Kong YY,Li J,et al.The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development.Cell,2000,103:41-50.
7Bucay N,Sarosi I,Dunstan CR,et al.Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.Gene Der,1998,12:1260-1268.
8Kong YY,Feige U,Sarosi I,et al.Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.Nature,1999,402:304-309.
10Lee JW,Chung HY,Ehrlich LA,et al.IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells.Blood,2004,103:2308-2315.
